{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:29:20Z","timestamp":1787315360446,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Deutsche Forschungsgesellschaft","award":["WE 2858\/5-1 \u2013 AOBJ: 661984"],"award-info":[{"award-number":["WE 2858\/5-1 \u2013 AOBJ: 661984"]}]},{"name":"Health Research Board Ireland","award":["CTN-2014-014"],"award-info":[{"award-number":["CTN-2014-014"]}]},{"name":"Health Research Board Ireland","award":["DIFA -2017-028"],"award-info":[{"award-number":["DIFA -2017-028"]}]},{"name":"Health Research Board Ireland","award":["DIFA-2018-006"],"award-info":[{"award-number":["DIFA-2018-006"]}]},{"name":"Health Research Board Ireland","award":["OLF-2018-1"],"award-info":[{"award-number":["OLF-2018-1"]}]},{"DOI":"10.13039\/501100001594","name":"Irish Heart Foundation","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100001594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"crossref","award":["T001719N"],"award-info":[{"award-number":["T001719N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Deutsche Forschungsgesellschaft","award":["WE 2858\/5-1 \u2013 AOBJ: 661984"],"award-info":[{"award-number":["WE 2858\/5-1 \u2013 AOBJ: 661984"]}]},{"name":"Health Research Board Ireland","award":["CTN-2014-014"],"award-info":[{"award-number":["CTN-2014-014"]}]},{"name":"Health Research Board Ireland","award":["DIFA -2017-028"],"award-info":[{"award-number":["DIFA -2017-028"]}]},{"name":"Health Research Board Ireland","award":["DIFA-2018-006"],"award-info":[{"award-number":["DIFA-2018-006"]}]},{"name":"Health Research Board Ireland","award":["OLF-2018-1"],"award-info":[{"award-number":["OLF-2018-1"]}]},{"DOI":"10.13039\/501100001594","name":"Irish Heart Foundation","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100001594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"crossref","award":["T001719N"],"award-info":[{"award-number":["T001719N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammation contributes to unstable atherosclerotic plaque and stroke. In randomised trials in patients with coronary disease, canukinumab (an interleukin-1B antagonist) and colchicine (a tubulin inhibitor with pleiotropic anti-inflammatory effects) reduced recurrent vascular events.<\/jats:p>\n                    <jats:p>Hypothesis: Anti-inflammatory therapy with low-dose colchicine plus usual care will reduce recurrent vascular events in patients with non-severe, non-cardioembolic stroke and TIA compared with usual care alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>CONVINCE is a multi-centre international (in 17 countries) Prospective, Randomised Open-label, Blinded-Endpoint assessment (PROBE) controlled Phase 3 clinical trial in 3154 participants. The intervention is colchicine 0.5\u2009mg\/day and usual care versus usual care alone (antiplatelet, lipid-lowering, antihypertensive treatment, lifestyle advice). Included patients are at least 40\u2009years, with non-severe ischaemic stroke (modified Rankin score \u22643) or high-risk TIA (ABCD2\u2009&amp;gt;\u20093, or positive DWI, or cranio-cervical artery stenosis) within 72\u2009hours-28\u2009days of randomisation, with qualifying stroke\/TIA most likely caused by large artery stenosis, lacunar disease, or cryptogenic embolism. Exclusions are stroke\/TIA caused by cardio-embolism or other defined cause (e.g. dissection), contra-indication to colchicine (including potential drug interactions), or incapacity for participation in a clinical trial. The anticipated median follow-up will be 36\u2009months. The primary analysis will be by intention-to-treat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome<\/jats:title>\n                    <jats:p>The primary outcome is time to first recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation with unstable angina (non-fatal or fatal).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>CONVINCE will provide high-quality randomised data on the efficacy and safety of anti-inflammatory therapy with colchicine for secondary prevention after stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schedule<\/jats:title>\n                    <jats:p>First-patient first-visit was December 2016. Recruitment to complete in 2021, follow-up to complete in 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2396987320972566","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T12:20:13Z","timestamp":1624018813000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":58,"title":["Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) \u2013 study protocol for a randomised controlled trial"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-6565","authenticated-orcid":false,"given":"Peter","family":"Kelly","sequence":"first","affiliation":[{"name":"Mater University Hospital and University College Dublin, Ireland 1"},{"name":"Health Research Board Stroke Clinical Trials Network, Ireland 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weimar","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informatik, Biometrie und Epidemiologie, Universit\u00e4tsklinikum Essen, University Duisburg-Essen, Essen, Germany 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lemmens","sequence":"additional","affiliation":[{"name":"VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium 5"},{"name":"VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium 5"},{"name":"University Hospitals Leuven, Department of Neurology, Leuven, Belgium 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Murphy","sequence":"additional","affiliation":[{"name":"Mater University Hospital and University College Dublin, Ireland 1"},{"name":"Health Research Board Stroke Clinical Trials Network, Ireland 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-5968","authenticated-orcid":false,"given":"Francisco","family":"Purroy","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, Hospitalt Universitari Arnau de Vilanova de Lleida, Spain 7"},{"name":"Universitat de Lleida, Biomedical Research Institute of Lleida (IRBLleida) , Universitat de Lleida (UdL), Spain 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Arsovska","sequence":"additional","affiliation":[{"name":"University Clinic of Neurology, Medical Faculty, University \u201cSs Cyril and Methodius\u201d, Skopje, North Macedonia 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natan M","family":"Bornstein","sequence":"additional","affiliation":[{"name":"Shaare-Zedek Medical Center, Jerusalem, Israel 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czlonkowska","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Fischer","sequence":"additional","affiliation":[{"name":"Stroke Centre and Clinical Trial Unit, University of Bern, Bern, Switzerland 12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6913-5526","authenticated-orcid":false,"given":"Ana Catarina","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland 13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Forbes","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Limerick, Limerick, Ireland 14"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-1543","authenticated-orcid":false,"given":"Michael D","family":"Hill","sequence":"additional","affiliation":[{"name":"University of Calgary & Foothills Medical Centre, Calgary, Alberta, Canada 15"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalius","family":"Jatuzis","sequence":"additional","affiliation":[{"name":"Centre of Neurology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Lithuania 16"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janika","family":"K\u00f5rv","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia 17"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kruuse","sequence":"additional","affiliation":[{"name":"Herlev Gentofte Hospital and University of Copenhagen, Denmark 18"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-5166","authenticated-orcid":false,"given":"Robert","family":"Mikulik","sequence":"additional","affiliation":[{"name":"International Clinical Research Center and Neurology Department, St. Anne\u2019s University Hospital and Masaryk University Brno, Czech Republic 19"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"J Nederkoorn","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centers (AUMC), Department of Neurology | Location AMC, Amsterdam, The Netherlands 20"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"HRB Clinical Research Facility Galway and National University of Ireland Galway, Ireland 21"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8484-0135","authenticated-orcid":false,"given":"Peter","family":"Sandercock","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, Edinburgh, UK 22"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tanne","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh UK 23"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d Hospital, National and Kapodistrian, University of Athens, School of Medicine, Athens, Greece 24"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal","family":"Walsh","sequence":"additional","affiliation":[{"name":"Mathematics Applications Consortium for Science and Industry and Health Research Institute, University of Limerick, Ireland 25"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Williams","sequence":"additional","affiliation":[{"name":"RCSI University of Medicine and Health Sciences and Beaumont Hospital, Dublin, Ireland 26"},{"name":"RCSI University of Medicine and Health Sciences and Beaumont Hospital, Dublin, Ireland 26"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7530-818X","authenticated-orcid":false,"given":"Marialuisa","family":"Zedde","sequence":"additional","affiliation":[{"name":"Neurology Unit, Stroke Unit, Azienda Unit\u00e0 Sanitaria locale-IRCCS di Reggio Emilia, Italy 27"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher I","family":"Price","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Newcastle University, Newcastle, UK 28"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"2026012113170375000_bibr1-2396987320972566","doi-asserted-by":"crossref","first-page":"e007267","DOI":"10.1161\/JAHA.117.007267","article-title":"Long-term risk of myocardial infarction compared to recurrent stroke after transient ischemic attack and ischemic stroke: systematic review and meta-analysis","volume":"7","author":"Boulanger","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026012113170375000_bibr2-2396987320972566","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1212\/01.WNL.0000110311.09970.83","article-title":"Early risk of recurrence by subtype of ischaemic stroke in population-based incidence studies","volume":"62","author":"Lovett","year":"2004","journal-title":"Neurology"},{"key":"2026012113170375000_bibr3-2396987320972566","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ana.21921","article-title":"Yield of systematic transcranial Doppler in patients with transient ischaemic attack","volume":"68","author":"Meseguer","year":"2010","journal-title":"Ann Neurol"},{"key":"2026012113170375000_bibr4-2396987320972566","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"key":"2026012113170375000_bibr5-2396987320972566","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/STROKEAHA.109.575373","article-title":"Stroke subtype classification to mechanism-specific and undetermined categories by TOAST, A-S-C-O and Causative Classification system \u2013 direct comparison in the North Dublin Population Stroke Study","volume":"41","author":"Marnane","year":"2010","journal-title":"Stroke"},{"key":"2026012113170375000_bibr6-2396987320972566","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"Atrial fibrillation in patients with cryptogenic stroke","volume":"370","author":"Gladstone","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113170375000_bibr7-2396987320972566","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113170375000_bibr8-2396987320972566","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012113170375000_bibr9-2396987320972566","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/STROKEAHA.108.534107","article-title":"Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes","volume":"40","author":"Amarenco","year":"2009","journal-title":"Stroke"},{"key":"2026012113170375000_bibr10-2396987320972566","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/jnnp-2016-314817","article-title":"Anti-inflammatory approaches to ischaemic stroke prevention","volume":"89","author":"Kelly","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113170375000_bibr11-2396987320972566","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012113170375000_bibr12-2396987320972566","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1097\/01.mjt.0000433937.07244.e1","article-title":"Colchicine: new insights to an old drug","volume":"22","author":"Stack","year":"2015","journal-title":"Am J Ther"},{"key":"2026012113170375000_bibr13-2396987320972566","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejim.2010.09.010","article-title":"Colchicine in clinical medicine. A guide for internists","volume":"21","author":"Cocco","year":"2010","journal-title":"Eur J Intern Med"},{"key":"2026012113170375000_bibr14-2396987320972566","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113170375000_bibr15-2396987320972566","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012113170375000_bibr16-2396987320972566","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/ene.14198","article-title":"Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis","volume":"27","author":"Katsanos","year":"2020","journal-title":"Eur J Neurol"},{"key":"2026012113170375000_bibr17-2396987320972566","author":"Colchicine for prevention of vascular inflammation in noncardioembolic stroke (CONVINCE) \u2013 a randomised clinical trial of low-dose colchicine for secondary prevention after stroke"},{"key":"2026012113170375000_bibr18-2396987320972566","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"key":"2026012113170375000_bibr19-2396987320972566","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1474-4422(19)30034-1","article-title":"regional, and national burden of stroke, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Johnson","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026012113170375000_bibr20-2396987320972566","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(15)00132-5","article-title":"Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study","volume":"14","author":"Li","year":"2015","journal-title":"Lancet Neurol"},{"key":"2026012113170375000_bibr21-2396987320972566","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1161\/STROKEAHA.119.025831","article-title":"Essen risk score in prediction of myocardial infarction after TIA or stroke without prior coronary artery disease","volume":"50","author":"Boulanger","year":"2019","journal-title":"Stroke"},{"key":"2026012113170375000_bibr22-2396987320972566","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolcumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012113170375000_bibr23-2396987320972566","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"2026012113170375000_bibr24-2396987320972566","first-page":"525","article-title":"Systematic review of C-reactive protein (CRP) and risk of recurrent events after ischaemic stroke or transient ischaemic attack (TIA)","volume":"4","author":"McCabe","year":"2019","journal-title":"Eur Stroke J"},{"key":"2026012113170375000_bibr25-2396987320972566","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/STROKEAHA.115.012166","article-title":"Inflammatory markers and outcomes after lacunar stroke levels of inflammatory markers in treatment of stroke study","volume":"47","author":"Boehme","year":"2016","journal-title":"Stroke"},{"key":"2026012113170375000_bibr26-2396987320972566","first-page":"19007682","article-title":"Interleukin-6 signalling effects on ischaemic stroke and other cardiovascular outcomes: a Mendelian Randomization study","author":"Georgakis","journal-title":"medRxiv"},{"key":"2026012113170375000_bibr27-2396987320972566","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/CIRCULATIONAHA.118.035905","article-title":"Genetically determined levels of circulating cytokines and risk of stroke","volume":"139","author":"Georgakis","year":"2019","journal-title":"Circulation"},{"key":"2026012113170375000_bibr28-2396987320972566","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1161\/STROKEAHA.119.025422","article-title":"Carotid plaque inflammation imaged by 18F-fluorodeoxyglucose positron emission tomography and risk of early recurrent stroke","volume":"50","author":"Kelly","year":"2019","journal-title":"Stroke"},{"key":"2026012113170375000_bibr29-2396987320972566","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012113170375000_bibr30-2396987320972566","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"2026012113170375000_bibr31-2396987320972566","first-page":"CD011047","article-title":"Colchicine for prevention of cardiovascular events","author":"Hemkens","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012113170375000_bibr32-2396987320972566","first-page":"CD012825","article-title":"Anti-inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack","volume":"5","author":"Coveney","year":"2020","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2396987320972566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2396987320972566","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/6\/2\/222\/64653521\/2396987320972566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/6\/2\/222\/64653521\/2396987320972566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:19:20Z","timestamp":1769019560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/6\/2\/222\/8271717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1177\/2396987320972566","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,6,1]]}}}